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S234 Poster Session IRelapsing disease is still the major cause of treatment failure. Addi-
tional strategies, such as maintenance therapy with novel agents or
judicious use of donor lymphocyte infusions merit further investiga-
tion for converting PR to CR and reducing relapse risk.204
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Following myeloablative conditioning due to high treatment-re-
lated mortality (TRM), some studies have shown an inferior out-
come using allogeneic HSCT compared to autologous transplant.
More recently, non-myeloablative (NMA) and reduced intensity
conditioning (RIC) for allogeneic HSCT was introduced. A prereq-
uisite for this approach is a significant graft-versus-myeloma effect,
which has not clearly been demonstrated. Between 1997 and 2005,
177 patients were reported to the CIBMTR following NMA
(n5 120) or RIC (n5 57) and an allogeneic HSCT from an HLA-
identical sibling donor. Median age was 50 years (range 24-69).
Planned tandem autologous transplant followed by allogeneic
HSCT was given to 105 of these patients. Most patients were given
peripheral blood stem cells (98%). Outcomes, with a median follow-
up of 55 months (range 3-98) and 25 months (range 3-76) respec-
tively for allogeneic HSCT and autologous transplant followed by
allogeneic HSCT, see Table below.
The following variables were significant in univariate outcomes
analyses and were therefore used in the multivariate modelling:
age, sex, performance status, IgG vs. non IgG myeloma, disease sta-
tus and chemosensitivity, prior lines of chemotherapy, donor-recip-
ient sex match, NMA vs. RIC, year of transplant and GVHD as the
time dependent covariate. The only factor on multivariate analysis
that increased the risk of TRM was acute GVHD (RR 2.38,
p5 0.018). Only chronic GVHD decreased the probability of re-
lapse on multivariate (RR 0.43, p5 0.012), but this effect was not
seen in patients with IgGmyeloma (n5 97, RR 0.7, p5 0.3) in com-
parison to all other types of myeloma (n5 80, RR 0.11, p5 0.004).
Improved PFS was associated with autologous + allogeneic HSCT
(RR 3.6, p5 0.001) and absence of acute GVHD (p5 0.001), but
not chronicGVHD (RR 0.9, p5 0.7). In conclusion, patients receiv-
ing allogeneic HCT for myeloma, chronic GVHD decreased the
probability of relapse, but only in patients with non-IgG myeloma.
PFS was improved in patients receiving autologous + allogeneic
HCT and was decreased in those with acute GVHD.
Outcomes Allo only Auto1AlloNumber of patients 72 105
Acute GVHD at 100 days, grades (1-4) 47 (37-60)% 37 (28-46)%
Chronic GVHD at 3 years 55 (43-67)% 58 (43-72)%
Treatment Related Mortality (TRM) at
3 years27 (17-38)% 16 (10-25)%Relapse at 3 years 48 (36-60)% 41 (29-54)%
Progression-free survival (PFS) at 3
years25 (15-37)% 42 (20-43)%Overall Survival at 3 years 45 (33-58)% 64 (53-75)%205
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The lack of specific molecules to define the multiple myeloma
(MM) malignant cells responsible for disease development and re-
lapse has hampered the evaluation of minimal residual disease
(MRD) in MM. PC development compromises an array of sub-
populations with distinctive phenotypes. Syndecan (CD138) is ex-
pressed in plasma cells (PC) and studies using CD138+ selected
cells may be problematic since earlier progenitors may be ex-
cluded. To define myeloma bone marrow (BM) progenitor phe-
notype we developed a multicolor flow cytometry assay to
study them. We have identified a CD138- subset that co-express
CD19+, CD27+ and identical kappa or lambda light chain re-
striction as the abnormal plasma cells, as previously shown by
others. Further characterization has shown that this subset co-ex-
presses the c-Kit (CD117) (20%) and Notch-1 receptors (90%) as
the hematopoietic stem cells (HSC) CD34+ counterpart. A small
percentage of this BM cells show aldehyde dehydrogenase
(ALDH) activity. Flow sorting of CD138- was feasible with
99% purity. Isolated populations were grown in methylcellulose
with 5% PHA-leukocyte conditioned medium. CD138+ cells
did not exhibit colony formation, and neither did the CD138-/
CD38+/CD19-/CD34- cells. Instead, CD138-/CD38+/CD19+/
CD34- cells were able to grow cell colonies (.100 cells) al-
though their efficiency was low (1 in 15,000). CD34+ cells
(HSC) also were able to grow cell colonies but with a significant
lesser efficiency compared to SCF, IL-3 and GM-CSF cytokine
stimulation. Cells harvested at day 14 from CD34+ and
CD138-/CD38+/CD19+/CD34- generated colonies showed
a lympho-plasmacytoid appearance. We showed that only
CD138-/CD38+/CD19+/CD34- cells, but not CD34 +HSC, dif-
ferentiated into a more mature syndecan (CD138+) expressing
cell as determined by flow cytometry. Isolated CD138-/CD38+/
CD19+/CD34- cells shown to be relatively bortezomib-resistant
when compared to CD138+ plasma cells. The lacking expression
of mature PC markers in this MM sub-population makes us hy-
pothesize that they represent a progenitor B cells that differenti-
ate into the malignant PC. Surrogate assays for stem cell activity
(long term culture-initiating cell (LTC-IC), cobblestone-area
forming cells (CAFC) and xenotransplant models should deter-
mine cancer stem cell activity of these cells. Research studies of
these CD138- MM putative progenitor cells may lead to develop
novel treatments to target MM subpopulations that may consti-
tute the MRD reservoir.206
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Introduction: Although the number of ASCTs performed for
MM continues to increase, the optimal mobilization strategy re-
mains unclear. Additionally, concern has arisen about the impact
of age and prior lenalidomide exposure on mobilization efficacy.
High dose etoposide has been previously shown to have antitumor
activity and efficacy in progenitor cell mobilization, and has a fa-
vorable safety profile when cytokine is also given (Gianni et al.,
JCO 1992). Here, we report on the efficacy and safety of mid-
dose etoposide and G-CSF as a mobilization regimen for pts
with MM.
Methods: Between May 2004 and June 2009, 152 pts with MM un-
derwent ASCT following the use of VP-16 (375 mg/m2 on D#1 and
D#2) and G-CSF (5mcg/kg twice daily from D#3 through the final
day of collection) for mobilization. 65 pts were female, 87 were
male, and median age was 56 yrs (range 17-72). Collection was
